SINGLE-AGENT IBRUTINIB IN RITUXIMAB-REFRACTORY PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM): UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE 3 SUBSTUDY (INNOVATETM)

Autor: Dimopoulos, M Trotman, J Tedeschi, A Matous, JV Macdonald, D Tam, C Tournilhac, O Ma, S Oriol, A Heffner, L others

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4c72cfceab46708d22c705425bd74f0e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2951150

Structure-function relationships of stem cell factor: an analysis based on a series of human-murine stem cell factor chimera and the mapping of a neutralizing monoclonal antibody

Autor: Matous, JV, Langley, K, Kaushansky, K

Publikováno v: Blood; July 1996, Vol. 88 Issue: 2 p437-444, 8p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.

Autor: Mailankody S; Myeloma Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mailanks@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. mailanks@mskcc.org., Matous JV; Colorado Blood Cancer Institute, Denver, CO, USA., Chhabra S; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Liedtke M; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA., Sidana S; Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University Hospital, Stanford, CA, USA., Oluwole OO; Vanderbilt University Medical Center, Nashville, TN, USA., Malik S; Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX, USA., Nath R; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Anwer F; Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA., Cruz JC; Texas Transplant Institute, San Antonio, TX, USA., Htut M; Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, USA., Karski EE; Allogene Therapeutics, South San Francisco, CA, USA., Lovelace W; Allogene Therapeutics, South San Francisco, CA, USA., Dillon M; Allogene Therapeutics, South San Francisco, CA, USA., Butz E; Allogene Therapeutics, South San Francisco, CA, USA., Ying W; Allogene Therapeutics, South San Francisco, CA, USA., Balakumaran A; Allogene Therapeutics, South San Francisco, CA, USA., Kumar SK; Mayo Clinic, Rochester, MN, USA.

Publikováno v: Nature medicine [Nat Med] 2023 Dec; Vol. 29 (12), pp. 3271.

Report of consensus panel 1 from the 11 ^th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients.

Autor: Buske C; University Hospital Ulm, Institute of Experimental Cancer Research, Ulm, Germany. Electronic address: christian.buske@uni-ulm.de., Castillo JJ; Dana Farber Cancer Institute, Harvard Medical School, Boston MA., Abeykoon JP; Mayo Clinic, Rochester MN., Advani R; Stanford University Medical Center, Stanford CA., Arulogun SO; University College London Hospitals, London UK., Branagan AR; Massachusetts General Hospital, Boston MA., Cao X; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., D'Sa S; University College London Hospitals, London UK., Hou J; Renji Hospital, Shanghai China., Kapoor P; Mayo Clinic, Rochester MN., Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Kersten MJ; Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam/LYMMCARE, Amsterdam, Netherlands., LeBlond V; Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris France., Leiba M; Faculty of Health Science, Ben- Gurion University of the Negev, Israel Assuta Ashdod University Hospital; Faculty of Health Science, Ben-Gurion University of the Negev, Negev, Israel Memorial Sloan Kettering Cancer Center, New York, NY., Matous JV; Colorado Blood Cancer Institute, Sarah Cannon Research Institute, Denver, CO., Paludo J; Mayo Clinic, Rochester MN., Qiu L; National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Tam CS; Alfred Health, Monash University, Melbourne, Australia., Tedeschi A; A.O. Ospedale Niguarda Ca' Granda, Milan, Italy., Thomas SK; University of Texas, MD Anderson Cancer Center, Houston, TX., Tohidi-Esfahani I; Concord Repatriation General Hospital, University of Sydney, Sydney, Australia., Varettoni M; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Vos JM; Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam/LYMMCARE, Amsterdam, Netherlands., Garcia-Sanz R; Hematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca, CIBERONC and Center for Cancer Research-IBMCC (University of Salamanca-CSIC), Salamanca, Spain., San-Miguel J; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red Cáncer, Pamplona, Spain., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Treon SP; Dana Farber Cancer Institute, Harvard Medical School, Boston MA., Trotman J; Concord Repatriation General Hospital, University of Sydney, Sydney, Australia.

Publikováno v: Seminars in hematology [Semin Hematol] 2023 Mar; Vol. 60 (2), pp. 73-79. Date of Electronic Publication: 2023 Mar 29.